TREA

79164550 - ARVEN

Follow

Information

  • Trademark
  • 79164550
  • Serial Number
    79164550
  • Registration Number
    5061369
  • Filing Date
    October 01, 2014
    10 years ago
  • Registration Date
    October 18, 2016
    8 years ago
  • Transaction Date
    April 26, 2025
    22 days ago
  • Status Date
    September 30, 2024
    7 months ago
  • Published for Opposition Date
    August 02, 2016
    8 years ago
  • Location Date
    October 18, 2016
    8 years ago
  • Status Code
    404
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    YAO, GRETTA
  • Attorney Docket Number
    T-3739 US MP
    Attorney Name
    Aylin Demirci
    Law Office Assigned Location Code
    M90
  • Owners
Information
Mark Drawing Code
4
Mark Identification
ARVEN
Case File Statements
  • GS0051: Pharmaceuticals and pharmaceutical preparations for the prevention and treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, allergy, ophthalmic diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, neutropenia, non-Hodgkin lymphoma, Crohn's Disease, autoimmune disorders, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors, contraceptive preparations, analgesics, anti-pyretics, anti-inflammatory preparations, anti-septic preparations, medicated lip balm, anesthetic spray for topical use, astringents, pediculicides, decongestants, antifungal agents, anti-infective pharmaceutical preparations, antacids, cold preparations in the nature of preparations for treating colds, menstrual symptom treatment preparations and dermatologicals; Pharmaceuticals and pharmaceutical preparations, namely, dry powder inhalers filled with pharmaceutical preparations for the treatment of asthma and respiratory diseases; Inhalation products, namely, inhalers filled with pharmaceutical preparations for the treatment of asthma, respiratory diseases; pharmaceutical preparations used in medical diagnostic procedures, namely, contrast media for use with x-ray, magnetic resonance and ultrasound equipment; veterinary preparations for medical use, namely, anesthetics, combination sedative, analgesic; veterinary preparations for medical use for the treatment of bacterial infections; pharmaceutical preparations, namely, Systemic anti-infectives, namely, antibacterial and antifungal pharmaceuticals; mineral preparations, namely, vitamin and mineral supplements, vitamin and mineral preparations for medical use, vitamin preparations and mineral supplements; Musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; Cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, calcium antagonists and cardiovascular treatment preparations and cardiovascular agents for medical purposes; Pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, analgesics, psychoanaleptics, psycoleptics, anti-epileptics, central nervous system drugs, anaesthetics, antiparkinson preparations; Pharmaceuticals for the treatment of respiratory diseases and asthma; Dermatological pharmaceutical products; Pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; Anti-diabetic pharmaceuticals; Pharmaceuticals for the treatment of bone diseases and joint diseases; Pharmaceuticals for the treatment of viral and infectious diseases; Pharmaceuticals for use as antineoplastic agents; Pharmaceuticals for the treatment of immune system related diseases and disorders; Pharmaceuticals for the treatment of kidney diseases; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals for ophthalmological use; pharmaceutical preparations for the treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, erectile dysfunction, respiratory diseases, allergy, ophthalmic diseases, containing one or more of the following active ingredients - cromolin sodium, amlodipin besylate, alendronate sodium, chlorazepate dipotassium, atropine sulphate, atorvastatin calcium, candesartan cilexetil, ceftriaxone sodium, ephedrine hcl, guaiphenesine, zafirlukast, donepezil hcl, diflunisal, dipyridamole, famotidine, losartan potassium, hydro-chlorothiazide, meloxicam, phenyleprine hcl, fexofenadine hcl, indapamide, sulfisoxazole, clopidogrel, lansoprazole, clarithromycin, flurbiprofen, nimesulide, pantoprazole, paracetamole, pilocarpine hcl, lisinopril, pseudoephedrine hcl, ciprofloxacin hcl, sertraline hcl, cyclopentolate hcl, dihydroergotoxine methansulfonate, terbinafine, timolol maleate, tiamphenicol, azithromycin, tenoxicam, fluconazole, digoxine, tioconazole, dimenhydrinate, quinidine arabogalactane sulphate, quinidine phenylethyl barbiturate, diltiazem hcl, buspirone hcl, amiodarone hcl, trazodone, difluprednate, enoxacin, lactulose, ketorolac, pentoxifylline, vitamin e, chlorhexidine, cetrimide, propyphenazone, caffeine, cetirizine, phenylpropanolamine, zolpidem, bacampicillin hcl, roxithromycin, sultamicillin tosilate, acetylsalicylic acid, ampicillin na, sulbactam na, sildenafil citrate, ambroxol hcl, ribavirin, loratadine, etodolac, omeprazole, oxybutynin chloride, quinidine sulphate, olanzapine, raloxifen, pioglitazone, moxifloxacin, rosiglitazone, sibutramin, carvedilol, montelukast, citalopram, gliclazide, cefaclor, ezetimibe, rofecoxib, quetiapine fumarate, metformin hcl, acarbose, chlorpheniramine maleate, nateglinide, leflunomide, valsartan, cefazolin sodium, diacerein, paroxetine, levofloxacin, levetiracetam, zolmitriptan, glibenclamide, tizanidine, perindopril erbumine, ramipril, ceftazidime, cefuroxime axetyl, thiocolchicoside, acamprosate, acetylcysteine, alpha calcidol, alpha lipoic acid, aripiprazole, atomoxetine, balsalazide disodium, butenafine hcl, calcitriol, carbonyl iron, folic acid, calcium carbonate, magnesium hydroxide, cefdinir, cefepime hcl, cefixime, cefpodoxime proxetil, cefprozil, cephalexine monohydrate, ciclesonide, cilazapril, cilostazol, cinitapride, citicoline, co-enzyme q10, darifenasin, deferiprone, dothiepin, duloxetine, eletriptan, escitalopram, esomeprazole, etoricoxib, felodipine, fenofibrate, ferrous sulphate, zinc sulphate, fluvastatin, frovatriptan, gabapentin, galantamine, gemifloxacin, ginkgo biloba, glimepride, granisetron, ibandronate, irbesartan, iron hydroxide polymaltose, lamivudine, lamotrigine, levetiracetam, letrozole, linezolide, memantine hcl, metoprolol, midodrine, mirtazapine, mizolastine, mosapride citrate dihydrate, mycophenolate mofetil, nebivolol, nefazodone, niacin, nitazoxanide, ondansetron, ornidazole, oxcarbazepine, pimecrolimus, pravastatin, pregabalin, rabeprazol, rebamipide, repaglinide, risedronate, risperidone, rivastigmine, rosuvastatin, saccharomyces boulardii, tacrolimus, tadalafil, tamsulosin hcl, tazaroten, tazobactam sodium, piperacillin sodium, tegaserod, telithromycin, terazocin, teriparatide, tolterodine tartrate, topiramate, trandolapril, trimethazidine, valacyclovir, valproate sodium, venlafaxine, voriconazole, ximelagatran, zaleplon, ziprasidone, zoledronic acid
  • TR0010: The wording "ARVEN" has no meaning in a foreign language.
Case File Event Statements
  • 5/7/2015 - 10 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 5/13/2015 - 10 years ago
    5 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 5/13/2015 - 10 years ago
    7 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 5/15/2015 - 10 years ago
    8 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 6/1/2015 - 9 years ago
    9 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 5/11/2015 - 10 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 5/11/2015 - 10 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 5/12/2015 - 10 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/13/2015 - 10 years ago
    6 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 6/1/2015 - 9 years ago
    10 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 1/5/2016 - 9 years ago
    18 - FINAL REFUSAL E-MAILED Type: GNFR
  • 6/2/2015 - 9 years ago
    11 - REFUSAL PROCESSED BY IB Type: RFNT
  • 11/12/2015 - 9 years ago
    12 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 11/30/2015 - 9 years ago
    13 - ASSIGNED TO LIE Type: ALIE
  • 12/10/2015 - 9 years ago
    14 - ASSIGNED TO LIE Type: ALIE
  • 12/15/2015 - 9 years ago
    15 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/15/2015 - 9 years ago
    16 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 1/5/2016 - 9 years ago
    17 - FINAL REFUSAL WRITTEN Type: CNFR
  • 7/13/2016 - 8 years ago
    28 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 8/2/2016 - 8 years ago
    29 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 1/5/2016 - 9 years ago
    19 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 6/23/2016 - 8 years ago
    20 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 6/23/2016 - 8 years ago
    21 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 6/23/2016 - 8 years ago
    22 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 6/23/2016 - 8 years ago
    23 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 6/23/2016 - 8 years ago
    24 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 6/29/2016 - 8 years ago
    25 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 7/13/2016 - 8 years ago
    26 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 7/13/2016 - 8 years ago
    27 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 8/2/2016 - 8 years ago
    30 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/23/2017 - 8 years ago
    37 - GENERIC MADRID TRANSACTION CREATED Type: XXCR
  • 2/23/2017 - 8 years ago
    38 - GENERIC MADRID TRANSACTION SENT TO IB Type: XXSS
  • 8/12/2016 - 8 years ago
    31 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 10/12/2016 - 8 years ago
    32 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 10/12/2016 - 8 years ago
    33 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 10/18/2016 - 8 years ago
    34 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 11/18/2016 - 8 years ago
    35 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 1/18/2017 - 8 years ago
    36 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 1/17/2024 - a year ago
    45 - GENERIC MADRID TRANSACTION CREATED Type: XXCR
  • 7/14/2017 - 7 years ago
    39 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 1/25/2018 - 7 years ago
    40 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 5/7/2020 - 5 years ago
    41 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 10/18/2021 - 3 years ago
    42 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3
  • 5/5/2023 - 2 years ago
    43 - CANCELLED SECTION 71 Type: C71T
  • 1/5/2024 - a year ago
    44 - TOTAL INVALIDATION OF REG EXT PROTECTION CREATED Type: INTR
  • 4/25/2025 - 23 days ago
    48 - DEATH OF INTERNATIONAL REGISTRATION Type: DETH
  • 4/25/2025 - 23 days ago
    49 - NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED Type: DENA
  • 2/5/2024 - a year ago
    47 - TOTAL INVALIDATION PROCESSED BY THE IB Type: INNT
  • 1/17/2024 - a year ago
    46 - GENERIC MADRID TRANSACTION SENT TO IB Type: XXSS